首页> 外文学位 >Antibiotic Resistance Study in Staphylococcus aureus by Label-free Quantitative Proteomics.
【24h】

Antibiotic Resistance Study in Staphylococcus aureus by Label-free Quantitative Proteomics.

机译:无标签定量蛋白质组学对金黄色葡萄球菌的抗生素耐药性研究。

获取原文
获取原文并翻译 | 示例

摘要

Methicillin-resistant Staphylococcus aureus (MRSA) is the leading cause of fatal bacterial infections in hospitals and has become a global health threat. Multi-drug resistance is the main reason for the failure of therapy. Although the antibiotic resistance mechanisms in bacteria have been studied for decades, there are few attempts at systems-wide investigations into how the bacteria respond to antibiotic stress. In this thesis, spectral counting-based label-free quantitative proteomics has been applied to study global responses in S. aureus treated with antibiotics. We developed a simple and easily repeated sample preparation procedure that is effective for extracting surface-associated proteins for the following spectral counting-based label-free quantitative proteomics experiments.;In our first experiment, sub-inhibitory dose of oxacillin, which is a first-line beta-lactam antibiotic, was first applied to the MRSA and methicillin-susceptible S. aureus (MSSA). On average, 1025 and 1013 proteins were identified at a false discovery rate threshold of 0.01, in the untreated groups of MRSA and MSSA. Differentially expressed proteins were obtained by comparing the spectral counts of identified proteins between the treated group and the untreated control group. Among the differentially expressed proteins, beta-lactamase and penicillin-binding protein 2a (PBP2a) were observed up-regulated uniquely in oxacillin-treated MRSA, which is consistent with the known beta-lactam resistant mechanisms of S. aureus. More interestingly, the peptidoglycan biosynthesis pathway and the pantothenate and CoA biosynthesis pathway were found up-regulated in both oxacillin-treated groups, indicating the common tolerance mechanism for both MRSA and MSSA.;In our second experiment, proteomics was employed to study the synergistic mechanism of a drug combination -- a new erythromycin derivative SIPI-8294 and oxacillin -- against MRSA. A systematic experimental workflow has been designed, in which cultured MRSA was exposed to sub-inhibitory doses of oxacillin, SIPI-8294, erythromycin, and combinations of SIPI-8294/oxacillin (SIPI-8294/Oxa) and erythromycin/oxacillin (Ery/Oxa, which do not show synergistic effect). Among the differentially expressed proteins, the expression levels of PBP2a and beta-lactamase were four times lower in the SIPI-8294/Oxa than in the Ery/Oxa treatment group. The results suggest that the synergistic mechanism may relate to interference with the known oxacillin resistance mechanism. Moreover, hierarchical clustering analysis for the differentially expressed proteins shows that SIPI-8294/Oxa elicits very different responses in the cell than those by the individual drugs or the Ery/Oxa combination. The data shows that the differentially expressed proteins potentially related to synergistic effect may impact oxidation-reduction homeostasis and cell wall biosynthesis.;In our third experiment, in order to mimic the clinical situation for treating infection, a lethal dose of SIPI-8294/Oxa was applied to MRSA cells, and the proteome responses were measured at 0.5 hour and 1 hour after treatment. A lethal dose of oxacillin alone, and a non-synergistic combination of Ery/Oxa at the same dose were used as the controls. Among the interesting findings, PBP2a and beta-lactamase were not detected nor found differentially expressed in the cells treated with lethal doses of SIPI-8294/Oxa or oxacillin, in contrast to the situation when sub-inhibitory doses were used. In the SIPI-8294/Oxa group, peptidoglycan hydrolase proteins, which are involved in cell wall degradation and remodeling, were up-regulated significantly. Interestingly, the proteome responses appear to be completely different between MRSA treated with a lethal dose and a sub-inhibitory dose of SIPI-8294/Oxa.;This work is among the first attempts to study antibiotic responses in S. aureus by state-of-the-art quantitative proteomics. The data obtained offered a more complete view of the cellular responses to antibiotics at different doses, and may be useful in guiding the development of new antibiotics or treatment strategies.;Keywords: Antibiotic resistance; Staphylococcus aureus; Label-free quantitative proteomics; Oxacillin, Synergistic effect; Mass spectrometry; sub-inhibitory dose response; lethal dose antibiotic response.
机译:耐甲氧西林金黄色葡萄球菌(MRSA)是医院致命细菌感染的主要原因,已成为全球健康威胁。多药耐药是治疗失败的主要原因。尽管已经研究了细菌中的抗生素抗性机制数十年,但很少有系统尝试研究细菌对抗生素压力的反应方式。在本文中,基于光谱计数的无标记定量蛋白质组学已被用于研究用抗生素治疗的金黄色葡萄球菌的整体反应。我们为以下基于光谱计数的无标记定量蛋白质组学实验开发了一种简单且易于重复的样品制备程序,该程序可有效提取与表面相关的蛋白质。;在我们的第一个实验中,奥沙西林的亚抑制剂量是首次线β-内酰胺类抗生素首先应用于MRSA和对甲氧西林敏感的金黄色葡萄球菌(MSSA)。在未经处理的MRSA和MSSA组中,平均以错误发现率阈值为0.01鉴定出1025和1013蛋白。通过比较治疗组和未治疗对照组之间鉴定的蛋白质的光谱计数,获得差异表达的蛋白质。在差异表达的蛋白质中,β-内酰胺酶和青霉素结合蛋白2a(PBP2a)在经奥沙西林处理的MRSA中被独特地上调,这与已知的金黄色葡萄球菌对β-内酰胺的耐药机制一致。更有趣的是,在奥沙西林治疗的两组中均发现肽聚糖的生物合成途径以及泛酸和CoA的生物合成途径均被上调,表明MRSA和MSSA的共同耐受机制。在我们的第二个实验中,蛋白质组学被用于研究协同作用药物组合的机理-一种新的红霉素衍生物SIPI-8294和奥沙西林-抗MRSA。设计了系统的实验流程,其中将培养的MRSA暴露于亚抑制剂量的奥沙西林,SIPI-8294,红霉素,以及SIPI-8294 /奥沙西林(SIPI-8294 / Oxa)和红霉素/奥沙西林(Ery / Oxa,没有协同作用)。在差异表达的蛋白质中,SIPI-8294 / Oxa中PBP2a和β-内酰胺酶的表达水平比Ery / Oxa治疗组低四倍。结果表明该协同机制可能与干扰已知的奥沙西林耐药机制有关。此外,差异表达蛋白质的层次聚类分析表明,SIPI-8294 / Oxa在细胞中引起的反应与单个药物或Ery / Oxa组合产生的反应截然不同。数据表明,可能与协同作用有关的差异表达蛋白可能会影响氧化还原稳态和细胞壁生物合成。;在我们的第三个实验中,为了模拟治疗感染的临床情况,使用了致命剂量的SIPI-8294 / Oxa将其应用于MRSA细胞,并在处理后0.5小时和1小时测量蛋白质组反应。单独使用致命剂量的奥沙西林和相同剂量的Ery / Oxa的非协同组合作为对照。在有趣的发现中,与使用亚抑制剂量的情况相反,在用致死剂量的SIPI-8294 / Oxa或奥沙西林处理的细胞中未检测到PBP2a和β-内酰胺酶,也未发现差异表达。在SIPI-8294 / Oxa组中,参与细胞壁降解和重塑的肽聚糖水解酶蛋白显着上调。有趣的是,在用致死剂量和亚抑制剂量的SIPI-8294 / Oxa治疗的MRSA中,蛋白质组反应似乎完全不同;这项工作是按状态研究金黄色葡萄球菌抗生素反应的首次尝试之一。最先进的定量蛋白质组学。所获得的数据提供了对不同剂量的抗生素对细胞反应的更完整视图,并且可能对指导开发新的抗生素或治疗策略很有用。金黄色葡萄球菌;无标记的定量蛋白质组学;奥沙西林,有协同作用;质谱;亚抑制剂量反应;致命剂量的抗生素反应。

著录项

  • 作者

    Liu, Xiaofen.;

  • 作者单位

    Hong Kong University of Science and Technology (Hong Kong).;

  • 授予单位 Hong Kong University of Science and Technology (Hong Kong).;
  • 学科 Chemical engineering.
  • 学位 Ph.D.
  • 年度 2015
  • 页码 180 p.
  • 总页数 180
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号